Kymera Therapeutics (KYMR) Q4 2025 earnings review
$1.6B War Chest Secures Runway to 2029 as KT-621 Advances
Kymera Therapeutics executed a masterclass in biotech capital management in Q4 2025. Leveraging positive Phase 1b data for its flagship STAT6 degrader (KT-621) reported in December, the company raised approximately $692 million in gross proceeds. This catapults its cash balance to $1.6 billion and eliminates financing overhangs by extending the runway into 2029. While R&D expenses and net losses are accelerating to fund multiple global Phase 2b trials, this is a planned and fully funded expansion. The primary challenge is no longer capital, but patience: the next major clinical readouts for KT-621 will not arrive until mid-to-late 2027.
🐂 Bull Case
With $1.6 billion in cash, Kymera is completely insulated from macro biotech funding winter cycles and can comfortably fund KT-621 through Phase 2b and into Phase 3 planning without toxic dilution.
The successful December 2025 Phase 1b data confirmed 'dupilumab-like' biomarker effects and clinical improvements, validating the platform and setting the stage for the current BROADEN2 and BREADTH Phase 2b trials.
🐻 Bear Case
With KT-621 Phase 2b data not expected until mid-to-late 2027, the stock lacks major near-term drivers for its flagship asset, leaving it vulnerable to broader market drifts or competitive developments in the immunology space.
Management has consistently benchmarked KT-621 against Dupixent's efficacy. This sets an incredibly high bar for the 2027 Phase 2b readouts; any result that is clinically meaningful but fails to match Dupixent could trigger a severe negative market reaction.
⚖️ Verdict: 🟢
Bullish. The $692M equity raise perfectly capitalizes on clinical momentum, decisively resolving the balance sheet question. Kymera is now a well-capitalized execution story, even if investors must wait until 2027 for the definitive Phase 2b verdicts.
Key Themes
Transformational Capital Raise Insulates from Macro Risks
In December 2025, Kymera completed a $602M underwritten equity offering (totaling $692M with the overallotment option). This move essentially removes macro financing risks—such as high interest rates or biotech sector pullbacks—from the investment thesis through the end of the decade, extending the runway from 2H 2028 directly into 2029.
KT-621 Pipeline Execution and Expansion
Execution remains rapid and stable. Following positive Phase 1b data in December, the company initiated the BREADTH Phase 2b trial in asthma (264 patients) and expanded the ongoing BROADEN2 Phase 2b trial in atopic dermatitis to include adolescents. The receipt of FDA Fast Track designation further validates the unmet need for an oral STAT6 degrader.
First-in-Class IRF5 Innovation Enters the Clinic
KT-579, a novel oral degrader of IRF5, commenced its Phase 1 healthy volunteer trial in February 2026. This is the first IRF5-directed mechanism to enter clinical testing, targeting master regulators of immunity to treat debilitating autoimmune conditions like lupus and rheumatoid arthritis. This provides a crucial secondary pipeline driver beyond STAT6.
The Catalyst Desert Contradicts the Momentum Narrative
While management touts entering the year 'with momentum,' the reality is that the next 18 months lack definitive clinical readouts for the flagship asset. BROADEN2 (AD) data is guided for mid-2027 and BREADTH (Asthma) for late-2027. This extended timeline contradicts the 'rapid execution' narrative seen in early Phase 1 trials and requires long-term investor patience.
Widening R&D Burn Rate
R&D expenses are accelerating, reaching $83.8M in Q4 2025 (up 17% YoY). While fully funded by the recent raise, the simultaneous execution of two massive global Phase 2b trials (KT-621) and a Phase 1 trial (KT-579) will continue to drive quarterly cash burn higher, making the company entirely dependent on clinical success to justify the expenditure.
The Dupilumab Expectations Trap
Management has historically built the KT-621 narrative entirely around achieving 'dupilumab-like' efficacy in a pill. By anchoring expectations to the gold standard of injectable biologics, Kymera creates a binary setup for the 2027 readouts where a 'good but not great' clinical profile may be severely punished by the market.
Other KPIs
Accelerating. Up 17% YoY from $71.8M in 24Q4. Full-year R&D expenses jumped 32% to $316.6M. This reflects the intense capital requirements of pivoting from early-stage clinical studies to large, multi-center global Phase 2b trials for KT-621, alongside scaling the research organization.
Decelerating. Dropped from $7.4M in 24Q4 and significantly down from early 2025 peaks ($22.1M in 25Q1, $11.5M in 25Q2). This revenue is entirely attributable to the Gilead Sciences collaboration and reflects the inherently lumpy nature of milestone payments in preclinical and early-clinical biotech partnerships.
Accelerating. The net loss widened sequentially and YoY (up from $70.8M in 24Q4). Full-year net loss ballooned to $311.4M compared to $223.9M in 2024. Despite the widening losses, the robust balance sheet renders this metric a non-issue for near-term survival.
Guidance
Accelerating corporate longevity. Previous guidance indicated a runway into the second half of 2028. The massive December equity raise adds at least six months to a year of operational safety, fully derisking the company through its Phase 2b readouts.
Stable. The timeline for the 200-patient atopic dermatitis trial is clearly established. This will be the most significant fundamental driver for the company's valuation over the next three years.
Stable. The 264-patient asthma trial is actively dosing, providing a secondary massive target market readout shortly after the atopic dermatitis data.
Stable. Healthy volunteer data for the IRF5 degrader will serve as the primary interim catalyst for the company while waiting for the larger STAT6 Phase 2b data in 2027.
Key Questions
Capital Deployment Strategy Post-Raise
With $1.6B in cash insulating operations through 2029, will Kymera accelerate the cadence of bringing discovery targets into the clinic beyond the stated 'one per year' goal, or will excess capital be reserved strictly for Phase 3 preparations for KT-621?
Bridging the Catalyst Gap
Given the lack of definitive KT-621 data until mid-2027, what intermediate trial metrics or enrollment updates will management provide to maintain investor confidence and track execution progress?
KT-579 Biomarker Expectations
For the upcoming KT-579 Phase 1 readout in 2H26, what specific level of IRF5 degradation and subsequent biomarker movement will constitute a definitive 'go' decision for advancing into patient studies?